Bruce V Taylor
Med J Aust 2022; 217 (4): . || doi: 10.5694/mja2.51645
Published online: 15 August 2022

MS risk is becoming less of a mystery as we gain a better understanding of its causes

Multiple sclerosis (MS) is a complex neuroinflammatory/ neurodegenerative disease of the central nervous system. Recent work 1 , 2 has significantly advanced our understanding of the aetiology of MS, emphasising the importance of infection with Epstein–Barr virus as a significant driver of MS risk. MS manifests clinically as neurological dysfunction affecting any area of the central nervous system, in particular the optic nerves, spinal cord, and brainstem. Most people with MS (90%) present with relapse onset MS where episodes of neurological dysfunction are followed by partial or full recovery but over time, disability almost invariably accumulates (secondary progressive MS). 3 In contrast, 10% of people present with progression from disease onset, termed progressive onset MS. 3 In the developed world, MS is one of the leading causes of neurological disability in young adults, and as the median age of onset in Australia is between 35 and 40 years, 4 it affects people in their most productive years. Consequently, the economic and social costs to individuals and the wider community are high. In 2017, we estimated the cost of MS to Australia was $1.7 billion annually and increasing significantly each year. 5 Currently, there is no cure for MS, but significant gains have been made in its treatment, particularly the use of highly effective disease‐modifying therapies and the development of comprehensive care through specialised MS clinics. However, no current treatment can stop or reverse the neurodegenerative component of the disease. 3

  • Bruce V Taylor

  • Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia



I receive National Health and Medical Research Council Leadership Fellow salary support.

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.
365电竞数据今日 企鹅电竞app登录网址(企鹅电竞选手下注) 电竞赚钱直播手机版网站 电竞赚钱战队数据app 英雄联盟竞猜比分入口 TT电竞比赛表